Raphael Kellman, M.D.

Dr. Raphael Kellman operates a functional medicine practice in New York, NY, where he has established a clinical focus on microbiome restoration, thyroid dysfunction, autoimmune conditions, and neurodegenerative disease management. As a board-certified internist and author of multiple books on microbiome science and thyroid health, Dr. Kellman integrates peptide therapy into comprehensive treatment protocols designed to address root causes rather than symptoms alone. His practice serves patients dealing with complex chronic conditions including Hashimoto's thyroiditis, inflammatory bowel disorders, chronic fatigue syndrome, and cognitive decline, with treatment plans built around detailed laboratory assessment and microbiome analysis.

Peptide therapy at this New York clinic includes thymosin alpha-1 for immune modulation in autoimmune patients, BPC-157 for gastrointestinal healing and tissue repair, and cerebrolysin for neuroprotection in patients with cognitive concerns or early neurodegenerative changes. Dr. Kellman employs peptides as part of multi-modal protocols that address gut barrier integrity, mitochondrial function, and systemic inflammation. Patients with thyroid disorders receive treatment plans that may combine peptide support with targeted nutritional interventions, bioidentical hormone optimization, and specific probiotic strains selected based on stool microbiome testing. The clinic's approach to chronic fatigue involves assessing viral reactivation, mitochondrial capacity, and adrenal function, with peptides used strategically to support cellular energy production and immune regulation.

Dr. Kellman's clinical methodology centers on what he terms the "microbiome medicine" framework, which examines the relationship between gut flora composition, intestinal permeability, and systemic disease manifestation. His protocols for autoimmune conditions typically begin with comprehensive testing including zonulin levels, lipopolysaccharide antibodies, and detailed microbiome sequencing to identify dysbiosis patterns. Treatment plans are constructed in phases, starting with gut restoration using specific prebiotics, targeted antimicrobials when indicated, and mucosal healing agents before introducing immune-modulating peptides. For neurodegenerative concerns, Dr. Kellman assesses the gut-brain axis through markers of neuroinflammation and intestinal barrier function, designing interventions that address both peripheral and central nervous system inflammation.

Patients at the New York practice undergo initial consultations lasting 60-90 minutes, during which Dr. Kellman reviews medical history, previous laboratory work, and current symptoms to develop individualized diagnostic plans. Follow-up visits track biomarker changes, symptom resolution, and treatment tolerance, with protocols adjusted based on objective measures rather than symptom reporting alone. The nursing staff coordinates laboratory scheduling, supplement protocols, and peptide administration education for patients new to injectable therapies. Patients report that the practice provides detailed written treatment plans with specific dosing schedules, expected timelines for improvement, and clear explanations of the rationale behind each intervention, which helps them understand the biological mechanisms being targeted.

The clinic operates exclusively through in-person consultations at its Manhattan location, requiring patients to visit the office for initial evaluations and periodic follow-ups, though some routine check-ins may be conducted via phone after the treatment relationship is established. Dr. Kellman's practice distinguishes itself through his published research on microbiome therapeutics and his integration of emerging peptide applications with established functional medicine testing. Patients seeking treatment for conditions that have not responded to conventional gastroenterology, endocrinology, or rheumatology care find the practice's focus on intestinal health as a foundation for systemic wellness particularly relevant, especially when dealing with overlapping autoimmune, thyroid, and neurological symptoms that suggest shared inflammatory pathways.